Exelixis, Inc. (EXEL) Revenue by Segment & Business Profile
Cabometyx was 90.1% of Exelixis, Inc.'s revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason
EXELExelixis, Inc.Follow EXEL — free
—
Price chart with a free account
- Market cap
- 16.0B
- P/E TTM
- 20.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What the company does
Exelixis, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 3 business lines: Cabometyx (90%), License (10%), Cometriq (0%). Trailing twelve-month revenue: $2.4 billion as of 2026-07-03.
Roles we read
from the filings, not the sector label- Commercial therapies
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 578M | 92.0% | +10.2% |
| Europe | 46M | 7.3% | +24.2% |
| Japan | 4M | 0.7% | -33.1% |
Exelixis, Inc. — questions
- What does Exelixis, Inc. do?
- Exelixis, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 3 business lines: Cabometyx (90%), License (10%), Cometriq (0%). Trailing twelve-month revenue: $2.4 billion as of 2026-07-03.
- How does Exelixis, Inc. make money?
- By the lines it reports in its SEC filings: Cabometyx 90.1%, License 9.5%, Cometriq 0.4% of revenue.
Every figure on this page comes from Exelixis, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.